FY2026 Earnings Forecast for COYA Issued By Chardan Capital

Coya Therapeutics, Inc. (NASDAQ:COYA) – Equities research analysts at Chardan Capital issued their FY2026 EPS estimates for Coya Therapeutics in a research report issued on Wednesday, May 14th. Chardan Capital analyst K. Nakae expects that the company will earn ($1.93) per share for the year. Chardan Capital currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Tuesday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.44). The company had revenue of $257.88 million for the quarter, compared to analyst estimates of $2.63 million.

Separately, D. Boral Capital reiterated a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research report on Tuesday, April 22nd.

Coya Therapeutics Trading Up 1.0%

Shares of COYA stock opened at $5.93 on Friday. Coya Therapeutics has a 1 year low of $4.65 and a 1 year high of $10.24. The firm’s 50 day moving average is $6.05 and its 200-day moving average is $6.17. The firm has a market capitalization of $99.18 million, a price-to-earnings ratio of -9.12 and a beta of 0.49.

Institutional Investors Weigh In On Coya Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC raised its stake in shares of Coya Therapeutics by 1,005.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock worth $30,000 after buying an additional 4,777 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new stake in shares of Coya Therapeutics during the first quarter worth approximately $65,000. XTX Topco Ltd bought a new stake in shares of Coya Therapeutics during the fourth quarter worth approximately $59,000. Jane Street Group LLC bought a new stake in shares of Coya Therapeutics during the fourth quarter worth approximately $74,000. Finally, Northern Trust Corp raised its stake in shares of Coya Therapeutics by 12.2% during the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock worth $164,000 after buying an additional 3,099 shares during the last quarter. 39.75% of the stock is owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.